These autoantibodies are frequently found in patients with CAD, present in 83% of cases, with 52% anti-TIF1γ and 31% anti-NXP-2, making them a valuable tool for screening for malignancy in DM with a sensitivity and specificity of 52% and 92%, respectively [17]. The gene discussed is TRIM33; the disease is dermatomyositis.